Previous 10 | Next 10 |
Outset Medical (OM +14.1%) has recorded the biggest intraday gain since Nov. 2020 on Thursday after projecting better-than-anticipated revenue guidance for 2022 despite a mixed performance on its Q4 2021 financials. The quarterly revenue jumped ~63% YoY to $28.2M expanding the annual revenue ...
Gainers: Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. Outset Medical (NASDAQ:OM) +10%. Masimo (NASDAQ:MASI) +8%. Vivos Therapeutics (NASDAQ:VVOS) +7%. Losers: 10x Genomics (NASDAQ:TXG) -16%. iSpecimen ISPC -10%. Poseida ...
Outset Medical, Inc. (OM) Q4 2021 Earnings Conference Call Feb 16, 2022 05:00 PM ET Company Participants Jim Mazzola - VP, IR Leslie Trigg - CEO Nabeel Ahmed - CFO Conference Call Participants Amit Hazan - Goldman Sachs Josh Jennings - Cowen Suraj Kalia - Oppenheimer Rick Wise - Stifel Daniel...
Gainers: Marin Software Incorporated MRIN +34%. Global-E Online GLBE +17%. KnowBe4 KNBE +11%. ACV Auctions ACVA +7%. Outset Medical OM +5%. Losers: 10x Genomics TXG -23%. Applovin Corporation APP -20%. Brightcove BCOV -...
Outset Medical press release (NASDAQ:OM): Q4 Non-GAAP EPS of -$0.77 misses by $0.10. Revenue of $28.15M (+63.2% Y/Y) beats by $1.72M. Shares +4.9%. Outset projects revenue for the full year 2022 to range from $142 million to $150 million ($140.44M consensus), which represents approximately 38...
Record Annual Revenue of $102.6 Million; 105% Year-over-Year Growth Outset Medical, Inc. (Nasdaq: OM) (“Outset” or the “Company”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis...
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will participate in a fireside chat at the SVB Leerink 11 th A...
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the fourth quarter and full year of 2021 after...
Outset Medical went public in September 2020, raising around $242 million in an IPO. The firm is commercializing an improved dialysis system in the United States. OM has grown revenue sharply but gross margins are low and the firm continues to produce high operating losses and cas...
Alnylam Pharmaceuticals (NASDAQ:ALNY), Crispr Therapeutics (NASDAQ:CRSP), Karuna Therapeutics (NASDAQ:KRTX) and six other biopharma names are among potential M&A candidates for 2022, according to Goldman Sachs. The nine new names have been added to Goldman Sach's Healthcare Strategic Asse...
News, Short Squeeze, Breakout and More Instantly...
Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that it will release financial results for the second quarter of 2024 after the close of trading on...
MONTREAL, July 24, 2024 (GLOBE NEWSWIRE) -- Osisko Metals Incorporated (the “ Company ” or “ Osisko Metals ”) ( TSX-V:OM ; OTCQX:OMZNF ; FRANKFURT:0B51 ) is pleased to provide an update on the activities being carried out this summer as part of the ...